title: Platelet reactivity in thromboelastometry. Revision of the FIBTEM test: a basic study.
abstract: This study aimed to investigate modifications to the FIBTEM test to better assess fibrinogen levels and the quality of fibrin polymerization in citrated blood using Multiplate impedance aggregometry to verify platelet inhibition. Blood samples from 26 healthy volunteers were subjected to thromboelastometry studies (EXTEM/FIBTEM tests) in accordance with the standard study protocol (cytochalasin D) and according to a modified protocol (synthetic IIbIIIa receptor antagonist vs. acetylsalicylic acid [ASA] + synthetic IIbIIIa receptor antagonist instead of cytochalasin D). Independent of thromboelastometry, Multiplate impedance aggregometry was used to assess the degree of restriction by the platelet blocked with the following treatments: (1) cytochalasin D, (2) synthetic IIbIIIa antagonist or (3) ASA + synthetic IIbIIIa antagonist to assess the aggregation response to activation with an agonist (ADP, collagen, thrombin receptor activating peptide-6 [TRAP-6], and arachidonic acid). Via aggregometry, cytochalasin D more weakly inhibited platelet aggregation than simultaneous administration of the -IIbIIIa receptor antagonist with ASA. However, total platelet aggregation inhibition was observed after simultaneous administration of cytochalasin D combined with a synthetic IIbIIIa receptor antagonist. In the thromboelastometry, a significant decrease of the A10, A20 and MCF parameters were observed in the EXTEM/FIBTEM tests after they were modified by the addition of a synthetic IIbIIIa receptor antagonist alone or in combination with ASA. In conclusion, in this Multiplate- and ROTEM-based laboratory approach, a two-way blockade (IIbIIIa-antagonist + cytochalasine D) was sufficient to completely inhibit procoagulant platelet function as observed by aggregometry and thromboelastometry.
authors.affiliation: a Department of General Vascular Surgery, Faculty of Medicine in Katowice , School of Health Science, Medical University of Silesia , Katowice , Poland.
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Biolik
authors.affiliation: b Department of Internal Medicine and Metabolic Diseases, Faculty of Medicine in Katowice , School of Health Science, Medical University of Silesia , Katowice , Poland.
authors.forename: Michał
authors.initials: M
authors.lastname: Kokot
authors.affiliation: a Department of General Vascular Surgery, Faculty of Medicine in Katowice , School of Health Science, Medical University of Silesia , Katowice , Poland.
authors.forename: Mariola
authors.initials: M
authors.lastname: Sznapka
authors.affiliation: a Department of General Vascular Surgery, Faculty of Medicine in Katowice , School of Health Science, Medical University of Silesia , Katowice , Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Święszek
authors.affiliation: c Faculty of Medicine in Katowice , Unit of Physiology, School of Health Care, Medical University of Silesia , Katowice , Poland.
authors.forename: Damian
authors.initials: D
authors.lastname: Ziaja
authors.affiliation: d Department of Biophysics, Faculty of Medicine in Katowice , School of Health Science Medical University of Silesia , Katowice , Poland.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Pawlicki
authors.affiliation: a Department of General Vascular Surgery, Faculty of Medicine in Katowice , School of Health Science, Medical University of Silesia , Katowice , Poland.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Ziaja
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D016718:Arachidonic Acid / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology*; D001780:Blood Coagulation Tests; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D003094:Collagen / Q000494:pharmacology; D015638:Cytochalasin D / Q000494:pharmacology*; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D039661:Integrin beta3 / Q000378:metabolism; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology; D015539:Platelet Activation / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects*; D040201:Platelet Membrane Glycoprotein IIb / Q000378:metabolism; D061251:Primary Cell Culture; D013916:Thrombelastography / Q000295:instrumentation / Q000379:methods / Q000592:standards*
chemical_list: D039661:Integrin beta3; D009842:Oligopeptides; D040201:Platelet Membrane Glycoprotein IIb; C504808:Ser-Phe-Phe-Leu-Arg-Asn; D015638:Cytochalasin D; D016718:Arachidonic Acid; D000244:Adenosine Diphosphate; D005337:Fibrin; D005340:Fibrinogen; D003094:Collagen; D001241:Aspirin
keywords: Acetylsalicylic acid; cytochalasin D; multiplate aggregometry; synthetic IIbIIIa receptor antagonist; thromboelastometry ROTEM® delta